Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC
{{output}}
Background: Immunotherapies have improved survival in patients with metastatic non-small cell lung cancer (mNSCLC), yet a substantial fraction of eligible patients remain untreated with immunotherapy in routine clinical practice.... ...
